Rare diseases
Investigational molecules
Locations
359 conditions with trials, the busiest first
849 trials across Europe, recruiting first
Study on GR1014 Gel to Prevent Skin Damage from Radiation in Breast Cancer Patients After Lumpectomy
FranceStudy on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus
FranceStudy on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients
The NetherlandsStudy on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma
GermanyStudy of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma
BelgiumStudy on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments
FranceStudy of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation
BelgiumStudy of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus
BulgariaStudy on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study
AustriaStudy on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis
GermanyStudy on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More
BelgiumStudy of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy
GermanyThe therapies tested most often in Skin and subcutaneous tissue disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
